RU2300525C2 - Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения - Google Patents

Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения Download PDF

Info

Publication number
RU2300525C2
RU2300525C2 RU2004112780/04A RU2004112780A RU2300525C2 RU 2300525 C2 RU2300525 C2 RU 2300525C2 RU 2004112780/04 A RU2004112780/04 A RU 2004112780/04A RU 2004112780 A RU2004112780 A RU 2004112780A RU 2300525 C2 RU2300525 C2 RU 2300525C2
Authority
RU
Russia
Prior art keywords
formula
compound
adamantylmethyl
amino
chloro
Prior art date
Application number
RU2004112780/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2004112780A (ru
Inventor
Лилиан ЭЛКАРАЗ (GB)
Лилиан ЭЛКАРАЗ
Тимоти ДЖОНСОН (GB)
Тимоти Джонсон
Майкл СТОКС (GB)
Майкл Стокс
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2004112780A publication Critical patent/RU2004112780A/ru
Application granted granted Critical
Publication of RU2300525C2 publication Critical patent/RU2300525C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2004112780/04A 2001-11-16 2002-11-12 Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения RU2300525C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103836-3 2001-11-16
SE0103836A SE0103836D0 (sv) 2001-11-16 2001-11-16 Novel compounds

Publications (2)

Publication Number Publication Date
RU2004112780A RU2004112780A (ru) 2005-10-10
RU2300525C2 true RU2300525C2 (ru) 2007-06-10

Family

ID=20286020

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004112780/04A RU2300525C2 (ru) 2001-11-16 2002-11-12 Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения

Country Status (29)

Country Link
US (1) US7129246B2 (enExample)
EP (1) EP1448195B1 (enExample)
JP (1) JP4559077B2 (enExample)
KR (1) KR20040058290A (enExample)
CN (1) CN1585640B (enExample)
AR (1) AR037534A1 (enExample)
AT (1) ATE344034T1 (enExample)
AU (1) AU2002347741B2 (enExample)
BR (1) BR0214142A (enExample)
CA (1) CA2464863A1 (enExample)
CO (1) CO5580747A2 (enExample)
DE (1) DE60215851T2 (enExample)
DK (1) DK1448195T3 (enExample)
ES (1) ES2274110T3 (enExample)
HU (1) HUP0402560A3 (enExample)
IL (1) IL161693A0 (enExample)
IS (1) IS7261A (enExample)
MX (1) MXPA04004498A (enExample)
MY (1) MY136430A (enExample)
NO (1) NO20042155L (enExample)
NZ (1) NZ532755A (enExample)
PL (1) PL370855A1 (enExample)
PT (1) PT1448195E (enExample)
RU (1) RU2300525C2 (enExample)
SE (1) SE0103836D0 (enExample)
TW (1) TW200407297A (enExample)
UA (1) UA77978C2 (enExample)
WO (1) WO2003041707A1 (enExample)
ZA (1) ZA200403682B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
KR20060037258A (ko) * 2003-05-29 2006-05-03 아스트라제네카 아베 Ｐ2Ｘ7-수용체 길항제 및 종양 괴사 인자 α를 포함하는제약 조성물
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
KR20090094336A (ko) 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
ES2388454T3 (es) * 2007-03-22 2012-10-15 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias
EP2155744A1 (en) 2007-04-10 2010-02-24 Lundbeck, H., A/S Heteroaryl amide analogues as p2x7 antagonists
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
BRPI1014902A2 (pt) 2009-04-14 2016-04-19 Affectis Pharmaceuticals Ag composto antagonista de p2x7r, sua composição e seus usos
MX2012013075A (es) 2010-05-14 2012-12-17 Affectis Pharmaceuticals Ag Metodos novedosos para preparacion de antagonistas p2x7r.
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
RU2014106611A (ru) 2011-07-22 2015-08-27 Актелион Фармасьютиклз Лтд Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
KR101576235B1 (ko) 2012-11-30 2015-12-11 한국생명공학연구원 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물
PL2931717T3 (pl) 2012-12-12 2017-05-31 Actelion Pharmaceuticals Ltd. Pochodne indolokarboksyamidu jako antagoniści receptora p2x7
AR094053A1 (es) 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x₇
EP2956457B1 (en) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
CN104163795B (zh) * 2014-08-19 2016-02-03 四川大学 盐酸烟酰美金刚胺溶剂合物、其制备方法和用途
CN104628615B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 含卤代苯的n-金刚烷酰胺类化合物、其制备方法及其用途
CN104628616B (zh) * 2015-02-12 2016-06-01 佛山市赛维斯医药科技有限公司 含对硝基苯基的n-金刚烷酰胺类化合物、其制备方法及用途
CN104628617B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 N-金刚烷酰胺类葡萄糖激酶活化剂、制备方法及其用途
CN104693084B (zh) * 2015-02-12 2016-03-16 佛山市赛维斯医药科技有限公司 含腈基苯基的n-金刚烷酰胺类化合物、其制备方法及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
RU99121844A (ru) * 1997-03-20 2001-07-20 Новартис Аг Некоторые циклические производные тио-замещенного амида ациламинокислоты

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) * 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) * 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US4027035A (en) * 1968-08-27 1977-05-31 Eli Lilly And Company Therapeutic uses of adamantanealkylamine compounds
IL53441A0 (en) * 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
AU5177390A (en) * 1989-03-10 1990-10-09 Idemitsu Kosan Company Limited Pyridine derivatives and their salts, and insecticidal/acaricidal agent containing the same as active ingredient
AU682051B2 (en) 1993-08-10 1997-09-18 James Black Foundation Limited Gastrin and CCK receptor ligands
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO2000061569A1 (en) 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
RU99121844A (ru) * 1997-03-20 2001-07-20 Новартис Аг Некоторые циклические производные тио-замещенного амида ациламинокислоты

Also Published As

Publication number Publication date
JP4559077B2 (ja) 2010-10-06
JP2005519028A (ja) 2005-06-30
RU2004112780A (ru) 2005-10-10
MXPA04004498A (es) 2004-08-11
HK1067048A1 (en) 2005-04-01
AR037534A1 (es) 2004-11-17
EP1448195B1 (en) 2006-11-02
HUP0402560A3 (en) 2009-03-02
ATE344034T1 (de) 2006-11-15
PL370855A1 (en) 2005-05-30
DK1448195T3 (da) 2007-02-12
AU2002347741B2 (en) 2008-03-13
IS7261A (is) 2004-05-13
UA77978C2 (en) 2007-02-15
DE60215851D1 (de) 2006-12-14
CN1585640B (zh) 2010-10-27
KR20040058290A (ko) 2004-07-03
NO20042155L (no) 2004-08-16
HUP0402560A2 (hu) 2005-04-28
ZA200403682B (en) 2005-08-03
CA2464863A1 (en) 2003-05-22
SE0103836D0 (sv) 2001-11-16
US7129246B2 (en) 2006-10-31
EP1448195A1 (en) 2004-08-25
NZ532755A (en) 2005-11-25
CN1585640A (zh) 2005-02-23
ES2274110T3 (es) 2007-05-16
WO2003041707A1 (en) 2003-05-22
MY136430A (en) 2008-10-31
BR0214142A (pt) 2004-09-14
US20050010052A1 (en) 2005-01-13
IL161693A0 (en) 2004-09-27
CO5580747A2 (es) 2005-11-30
TW200407297A (en) 2004-05-16
PT1448195E (pt) 2007-02-28
DE60215851T2 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
RU2300525C2 (ru) Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения
AU2002347741A1 (en) N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
EP3454854B1 (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US4923986A (en) Derivatives of physiologically active substance K-252
CA2861150C (en) Morphinan derivative
EP1352895B1 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
EP1292590B1 (en) Admantane derivatives
JP2005519028A5 (enExample)
KR20110019440A (ko) 아폽토시스 프로모터 ａｂｔ－２６３의 제조 방법
EP3611171B1 (en) Method for synthesis of eliglustat and intermediate compounds thereof
CZ298578B6 (cs) Heterocyklickou skupinou substituovaná tricyklická sloucenina a farmaceutický prostredek ji obsahující
DE69403084T2 (de) Benzopyrane und diese enthaltende pharmazeutische zusammenstellungen
WO1999065881A1 (en) Heterocyclic compounds as hypoglycemic agents
WO2009072062A2 (en) Novel derivatives of dihydroxypyrrolidine as anti-cancer compounds
HK1067048B (en) N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
RU2272025C2 (ru) Производные адамантана, способы их получения, фармацевтическая композиция на их основе и способ ее получения, способы лечения ревматоидного артрита и хронического обструктивного заболевания легких
JPS61225153A (ja) アミン誘導体
HK40005952A (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
HK40005952B (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
JPS59516B2 (ja) Ｎ− （ １− アダマンチルメチル ） −ｎ’− シンナミルピペラジンノ セイゾウホウホウ
HK1057036B (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
JPS591271B2 (ja) Ｎ− （ １− アダマンタンカルボニル ） − ピペラジンノ セイゾウホウ
HK1154568B (en) A process for the preparation of the apoptosis promoter abt-263
HK1057035B (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20081113